Mountain View, United States
ImpriMed, Inc., a Silicon Valley-based startup founded in 2017, is at the forefront of precision medicine with its focus on AI-driven personalized cancer care. The company’s slogan, "AI-driven Personalized Medicine for Cancer Care", perfectly encapsulates its mission to revolutionize oncology treatment.
Leveraging artificial intelligence, ImpriMed has developed pioneering drug response prediction technology to enhance treatment efficacy, reduce costs, and improve patient outcomes. Since its inception, their technology has been utilized across more than 40 U.S. states, conducting over 21,000 blood cancer tests on canines and felines by 2024.
In a recently closed $23.00M Series A funding round on November 10, 2023, significant backing was secured from prominent investors, including Murex Partners, SBVA, Ignite Innovation Fund, HRZ, SAMYANG CHEMICAL GROUP, Byucksan, SK Telecom, and KDB Industrial Bank. This capital infusion will propel ImpriMed into extending its transformative AI-driven technologies to human healthcare, setting a new standard in the future of oncology treatment.
Vet-AI
